keyword
https://read.qxmd.com/read/37627073/multi-institutional-evaluation-of-pathologists-assessment-compared-to-immunoscore
#1
JOURNAL ARTICLE
Joseph Willis, Robert A Anders, Toshihiko Torigoe, Yoshihiko Hirohashi, Carlo Bifulco, Inti Zlobec, Bernhard Mlecnik, Sandra Demaria, Won-Tak Choi, Pavel Dundr, Fabiana Tatangelo, Annabella Di Mauro, Pamela Baldin, Gabriela Bindea, Florence Marliot, Nacilla Haicheur, Tessa Fredriksen, Amos Kirilovsky, Bénédicte Buttard, Angela Vasaturo, Lucie Lafontaine, Pauline Maby, Carine El Sissy, Assia Hijazi, Amine Majdi, Christine Lagorce, Anne Berger, Marc Van den Eynde, Franck Pagès, Alessandro Lugli, Jérôme Galon
BACKGROUND: The Immunoscore (IS) is a quantitative digital pathology assay that evaluates the immune response in cancer patients. This study reports on the reproducibility of pathologists' visual assessment of CD3+- and CD8+-stained colon tumors, compared to IS quantification. METHODS: An international group of expert pathologists evaluated 540 images from 270 randomly selected colon cancer (CC) cases. Concordance between pathologists' T-score, corresponding hematoxylin-eosin (H&E) slides, and the digital IS was evaluated for two- and three-category IS...
August 10, 2023: Cancers
https://read.qxmd.com/read/36672367/multicenter-international-study-of-the-consensus-immunoscore-for-the-prediction-of-relapse-and-survival-in-early-stage-colon-cancer
#2
JOURNAL ARTICLE
Bernhard Mlecnik, Alessandro Lugli, Gabriela Bindea, Florence Marliot, Carlo Bifulco, Jiun-Kae Jack Lee, Inti Zlobec, Tilman T Rau, Martin D Berger, Iris D Nagtegaal, Elisa Vink-Börger, Arndt Hartmann, Carol I Geppert, Julie Kolwelter, Susanne Merkel, Robert Grützmann, Marc Van den Eynde, Anne Jouret-Mourin, Alex Kartheuser, Daniel Léonard, Christophe Remue, Julia Wang, Prashant Bavi, Michael H A Roehrl, Pamela S Ohashi, Linh T Nguyen, SeongJun Han, Heather L MacGregor, Sara Hafezi-Bakhtiari, Bradly G Wouters, Giuseppe V Masucci, Emilia K Andersson, Eva Zavadova, Michal Vocka, Jan Spacek, Lubos Petruzelka, Bohuslav Konopasek, Pavel Dundr, Helena Skalova, Kristyna Nemejcova, Gerardo Botti, Fabiana Tatangelo, Paolo Delrio, Gennaro Ciliberto, Michele Maio, Luigi Laghi, Fabio Grizzi, Tessa Fredriksen, Bénédicte Buttard, Lucie Lafontaine, Pauline Maby, Amine Majdi, Assia Hijazi, Carine El Sissy, Amos Kirilovsky, Anne Berger, Christine Lagorce, Christopher Paustian, Carmen Ballesteros-Merino, Jeroen Dijkstra, Carlijn van de Water, Shannon van Lent-van Vliet, Nikki Knijn, Ana-Maria Mușină, Dragos-Viorel Scripcariu, Boryana Popivanova, Mingli Xu, Tomonobu Fujita, Shoichi Hazama, Nobuaki Suzuki, Hiroaki Nagano, Kiyotaka Okuno, Toshihiko Torigoe, Noriyuki Sato, Tomohisa Furuhata, Ichiro Takemasa, Prabhu Patel, Hemangini H Vora, Birva Shah, Jayendrakumar B Patel, Kruti N Rajvik, Shashank J Pandya, Shilin N Shukla, Yili Wang, Guanjun Zhang, Yutaka Kawakami, Francesco M Marincola, Paolo A Ascierto, Bernard A Fox, Franck Pagès, Jérôme Galon
BACKGROUND: The prognostic value of Immunoscore was evaluated in Stage II/III colon cancer (CC) patients, but it remains unclear in Stage I/II, and in early-stage subgroups at risk. An international Society for Immunotherapy of Cancer (SITC) study evaluated the pre-defined consensus Immunoscore in tumors from 1885 AJCC/UICC-TNM Stage I/II CC patients from Canada/USA (Cohort 1) and Europe/Asia (Cohort 2). METHODS: Digital-pathology is used to quantify the densities of CD3+ and CD8+ T-lymphocyte in the center of tumor (CT) and the invasive margin (IM)...
January 8, 2023: Cancers
https://read.qxmd.com/read/36139506/clinical-performance-of-the-consensus-immunoscore-in-colon-cancer-in-the-asian-population-from-the-multicenter-international-sitc-study
#3
JOURNAL ARTICLE
Bernhard Mlecnik, Toshihiko Torigoe, Gabriela Bindea, Boryana Popivanova, Mingli Xu, Tomonobu Fujita, Shoichi Hazama, Nobuaki Suzuki, Hiroaki Nagano, Kiyotaka Okuno, Yoshihiko Hirohashi, Tomohisa Furuhata, Ichiro Takemasa, Prabhudas Patel, Hemangini Vora, Birva Shah, Jayendrakumar B Patel, Kruti N Rajvik, Shashank J Pandya, Shilin N Shukla, Yili Wang, Guanjun Zhang, Takayuki Yoshino, Hiroya Taniguchi, Carlo Bifulco, Alessandro Lugli, Jiun-Kae Jack Lee, Inti Zlobec, Tilman T Rau, Martin D Berger, Iris D Nagtegaal, Elisa Vink-Börger, Arndt Hartmann, Carol I Geppert, Julie Kolwelter, Susanne Merkel, Robert Grützmann, Marc Van den Eynde, Anne Jouret-Mourin, Alex Kartheuser, Daniel Léonard, Christophe Remue, Julia Wang, Prashant Bavi, Michael H A Roehrl, Pamela S Ohashi, Linh T Nguyen, SeongJun Han, Heather L MacGregor, Sara Hafezi-Bakhtiari, Bradly G Wouters, Giuseppe V Masucci, Emilia Andersson, Eva Zavadova, Michal Vocka, Jan Spacek, Lubos Petruzelka, Bohuslav Konopasek, Pavel Dundr, Helena Skalova, Kristyna Nemejcova, Gerardo Botti, Fabiana Tatangelo, Paolo Delrio, Gennaro Ciliberto, Michele Maio, Luigi Laghi, Fabio Grizzi, Florence Marliot, Tessa Fredriksen, Bénédicte Buttard, Lucie Lafontaine, Pauline Maby, Amine Majdi, Assia Hijazi, Carine El Sissy, Amos Kirilovsky, Anne Berger, Christine Lagorce, Christopher Paustian, Carmen Ballesteros-Merino, Jeroen Dijkstra, Carlijn Van de Water, Shannon van Lent-van Vliet, Nikki Knijn, Ana-Maria Mușină, Dragos-Viorel Scripcariu, Francesco M Marincola, Paolo A Ascierto, Bernard A Fox, Franck Pagès, Yutaka Kawakami, Jérôme Galon
BACKGROUND: In this study, we evaluated the prognostic value of Immunoscore in patients with stage I-III colon cancer (CC) in the Asian population. These patients were originally included in an international study led by the Society for Immunotherapy of Cancer (SITC) on 2681 patients with AJCC/UICC-TNM stages I-III CC. METHODS: CD3+ and cytotoxic CD8+ T-lymphocyte densities were quantified in the tumor and invasive margin by digital pathology. The association of Immunoscore with prognosis was evaluated for time to recurrence (TTR), disease-free survival (DFS), and overall survival (OS)...
September 6, 2022: Cancers
https://read.qxmd.com/read/35952316/immunoscore-is-prognostic-in-low-risk-and-high-risk-stage-iii-colon-carcinomas-treated-with-adjuvant-infusional-fluorouracil-leucovorin-and-oxaliplatin-in-a-phase-iii-trial
#4
JOURNAL ARTICLE
Frank A Sinicrope, Qian Shi, Aurelie Catteau, Graham M Poage, Tyler J Zemla, Bernhard Mlecnik, Al B Benson, Sharlene Gill, Richard M Goldberg, Morton S Kahlenberg, Suresh G Nair, Anthony F Shields, Thomas C Smyrk, Jerome Galon, Steven R Alberts
PURPOSE: The recommended duration of adjuvant fluoropyrimidine and oxaliplatin chemotherapy for patients with stage III colon cancer is based on tumor classification into clinically low-risk (T1-3 N1 ) and high-risk (T4 or N2 ) groups. We determined whether Immunoscore can enhance prognostication within these risk groups. MATERIALS AND METHODS: Patients with stage III colon carcinomas (N = 600) were randomly selected from the infusional fluorouracil, leucovorin, and oxaliplatin arm of adjuvant trial NCCTG N0147 (Alliance for Clinical Trials in Oncology)...
August 2022: JCO Precision Oncology
https://read.qxmd.com/read/35626126/tumor-infiltrating-lymphocytes-tils-in-early-breast-cancer-patients-high-cd3-cd8-and-immunoscore-are-associated-with-a-pathological-complete-response
#5
JOURNAL ARTICLE
Bernardo Leon Rapoport, Simon Nayler, Bernhard Mlecnik, Teresa Smit, Liezl Heyman, Isabelle Bouquet, Marine Martel, Jérôme Galon, Carol-Ann Benn, Ronald Anderson
BACKGROUND: Tumor-infiltrating lymphocytes are associated with a better prognosis in early triple-negative breast cancer (TNBC). These cells can be enumerated in situ by the "Immunoscore Clinical Research" (ISCR). The original Immunoscore® is a prognostic tool that categorizes the densities of CD3+ and CD8+ cells in both the invasive margin (IM) and center of the tumor (CT) in localized colon cancer, yielding a five-tiered classification (0-4). We evaluated the prognostic potential of ISCR and pathological complete response (pCR) following neoadjuvant chemotherapy (NACT)...
May 20, 2022: Cancers
https://read.qxmd.com/read/35141052/immune-sunrise-from-the-immunome-to-the-cancer-immune-landscape
#6
JOURNAL ARTICLE
Gabriela Bindea, Bernhard Mlecnik, Jérôme Galon
The complex dynamics of the tumor-immune interaction during tumor progression have been characterized by integrating genomic and proteomic experiments. The Immunome, a reference compendium of markers for the majority of immune cell subpopulations was used to describe the immune landscape in cancer. The immune contexture is at the cornerstone in the success of cancer immunotherapies. Markers with the highest clinical relevance were summarized as the consensus immunoscore. This immune evaluation refines the prognosis of the patients and the chemotherapy decision-making process and was introduced as essential and desirable diagnostic criteria into three major international guidelines...
2022: Oncoimmunology
https://read.qxmd.com/read/33996269/tumor-spread-or-siege-immunity-dissemination-to-distant-metastasis-or-not
#7
JOURNAL ARTICLE
Gabriela Bindea, Bernhard Mlecnik, Jérôme Galon
Metastasis is the leading cause of cancer mortality. We have investigated the tumor microenvironment at all metastatic cascade steps (early-metastasic dissemination, synchronous metastasis, metachronous metastasis) to delineate the impact of tumor and immune parameters to this process. Tumors with and without signs of early metastasis invasion (venous-emboli, lymphatic-invasion, perineural-invasion, collectively, VELIPI) had similar levels of inflammatory and immunosuppressive molecules. Cancer mutations, gene expression levels or chromosomal instability did not significantly differ in primary tumors from patients with or without metastasis...
April 25, 2021: Oncoimmunology
https://read.qxmd.com/read/33868790/license-to-kill-microsatellite-instability-and-immune-contexture
#8
JOURNAL ARTICLE
Pauline Maby, Gabriela Bindea, Bernhard Mlecnik, Jérôme Galon
Colorectal cancers (CRCs) with microsatellite instability (MSI) are due to a defect in the DNA mismatch repair (MMR) system resulting in an accumulation of frame-shift mutations. They are characterized by a tumor microenvironment richer in cytotoxic CD8 T-cells (CTLs) and a better prognosis compared to microsatellite stable (MSS) CRCs. The mechanisms by which defective MMR system may influence tumor-infiltrating immune cells and their impact on patient survival were still unclear. Thus, we performed a comprehensive analysis of MSI colorectal tumors...
April 2, 2021: Oncoimmunology
https://read.qxmd.com/read/33628626/expand-to-shield-il-15-and-in-situ-lymphocytic-proliferation
#9
REVIEW
Gabriela Bindea, Bernhard Mlecnik, Jérôme Galon
The tumor microenvironment includes a complex network of cytokines and chemokines that contribute to shaping the intratumoral immune reaction. Understanding the mechanisms leading to immune-hot (Immunoscore-high) altered (excluded and immunosuppressed) and cold tumors are of critical importance for successful anti-cancer therapies. Two essential mechanisms are highlighted. Specific chemokines and adhesion molecules appeared to target and attract immune effector T cells to the tumor microenvironment and to specific regions within the tumor...
February 12, 2021: Oncoimmunology
https://read.qxmd.com/read/33525361/the-immunoscore-in-localized-urothelial-carcinoma-treated-with-neoadjuvant-chemotherapy-clinical-significance-for-pathologic-responses-and-overall-survival
#10
JOURNAL ARTICLE
Elise F Nassif, Bernhard Mlecnik, Constance Thibault, Marie Auvray, Daniela Bruni, Alexandre Colau, Eva Compérat, Gabriela Bindea, Aurélie Catteau, Aurélie Fugon, Isabelle Boquet, Marine Martel, Philippe Camparo, Pierre Colin, Roubini Zakopoulou, Aristotelis Bamias, Mostefa Bennamoun, Xavier Barthere, Bruno D'acremont, Marine Lefevre, Francois Audenet, Arnaud Mejean, Virginie Verkarre, Stéphane Oudard, Jérôme Galon
(1) Background-The five-year overall survival (OS) of muscle-invasive bladder cancer (MIBC) with neoadjuvant chemotherapy and cystectomy is around 50%. There is no validated biomarker to guide the treatment decision. We investigated whether the Immunoscore (IS) could predict the pathologic response to neoadjuvant chemotherapy and survival outcomes. (2) Methods-This retrospective study evaluated the IS in 117 patients treated using neoadjuvant chemotherapy for localized MIBC from six centers (France and Greece)...
January 28, 2021: Cancers
https://read.qxmd.com/read/33457100/multiverse-of-immune-microenvironment-in-metastatic-colorectal-cancer
#11
JOURNAL ARTICLE
Marc Van den Eynde, Bernhard Mlecnik, Gabriela Bindea, Jérôme Galon
The comprehensive analysis of patients with a complete resection of all metastases reveals the heterogeneity of the colorectal metastatic disease and its clinical impact. Complex tumor immune interrelations shape the metastatic landscape, not only in terms of number and size of lesions, or mutational pattern, but also in terms of immune cell infiltrate. Significantly higher densities of T-cells and lower density of B-cells were quantified in the tumor microenvironment of metastases compared with primary tumors...
September 29, 2020: Oncoimmunology
https://read.qxmd.com/read/33110705/immunity-to-live-an-immunopathoscore-using-the-consensus-immunoscore-to-best-define-the-risk-of-recurrence-and-death-in-stage-iv-metastatic-patients
#12
REVIEW
Pamela Baldin, Marc Van den Eynde, Bernhard Mlecnik, Jérôme Galon
The consensus Immunoscore is a routine assay quantifying the adaptive immune response within the tumor microenvironment. Its evaluation in the primary tumor of patients with stages I/II/III colorectal cancer (CRC) has prognostic value that has been confirmed in multiple studies. For metastatic patients, the evaluation of the consensus Immunoscore within resected metastases also significantly predicts the recurrence and survival of Stage IV patients. Since recurrence rates post-surgery are still very high, it is important to best evaluate risk parameters using the main patho-molecular and immune parameters...
October 13, 2020: Oncoimmunology
https://read.qxmd.com/read/32923167/metastasis-immune-based-scores-predict-patient-survival
#13
JOURNAL ARTICLE
Bernhard Mlecnik, Gabriela Bindea, Marc Van den Eynde, Jérôme Galon
Treatment of metastatic colorectal cancer is based upon the assumption that metastases are homogeneous within a patient. A comprehensive analysis of all metastases of each patient revealed the heterogeneity of the colorectal metastatic disease and its clinical impact. Complex tumor-immune interrelations shape the metastatic landscape. Adaptive immune cells and Immunoscore quantified in a random metastatic biopsy predict clinical outcome and their evaluation in the tumor microenvironment of the least infiltrated metastasis most accurately predict long-term survival...
August 20, 2020: Oncoimmunology
https://read.qxmd.com/read/32902189/prognostic-assessment-of-resected-colorectal-liver-metastases-integrating-pathological-features-ras-mutation-and-immunoscore
#14
JOURNAL ARTICLE
Pamela Baldin, Marc Van den Eynde, Bernhard Mlecnik, Gabriela Bindea, Gabriela Beniuga, Javier Carrasco, Nacilla Haicheur, Florence Marliot, Lucie Lafontaine, Tessa Fredriksen, Nicolas Lanthier, Catherine Hubert, Benoît Navez, Nicolas Huyghe, Franck Pagès, Anne Jouret-Mourin, Jérôme Galon, Mina Komuta
Surgical resection of colorectal liver metastases combined with systemic treatment aims to maximize patient survival. However, recurrence rates are very high postsurgery. In order to assess patient prognosis after metastasis resection, we evaluated the main patho-molecular and immune parameters of all surgical specimens. Two hundred twenty-one patients who underwent, after different preoperative treatment, curative resection of 582 metastases were analyzed. Clinicopathological parameters, RAS tumor mutation, and the consensus Immunoscore (I) were assessed for all patients...
January 2021: Journal of Pathology. Clinical Research
https://read.qxmd.com/read/32897827/multicenter-international-society-for-immunotherapy-of-cancer-study-of-the-consensus-immunoscore-for-the-prediction-of-survival-and-response-to-chemotherapy-in-stage-iii-colon-cancer
#15
MULTICENTER STUDY
Bernhard Mlecnik, Carlo Bifulco, Gabriela Bindea, Florence Marliot, Alessandro Lugli, J Jack Lee, Inti Zlobec, Tilman T Rau, Martin D Berger, Iris D Nagtegaal, Elisa Vink-Börger, Arndt Hartmann, Carol Geppert, Julie Kolwelter, Susanne Merkel, Robert Grützmann, Marc Van den Eynde, Anne Jouret-Mourin, Alex Kartheuser, Daniel Léonard, Christophe Remue, Julia Y Wang, Prashant Bavi, Michael H A Roehrl, Pamela S Ohashi, Linh T Nguyen, SeongJun Han, Heather L MacGregor, Sara Hafezi-Bakhtiari, Bradly G Wouters, Giuseppe V Masucci, Emilia K Andersson, Eva Zavadova, Michal Vocka, Jan Spacek, Lubos Petruzelka, Bohuslav Konopasek, Pavel Dundr, Helena Skalova, Kristyna Nemejcova, Gerardo Botti, Fabiana Tatangelo, Paolo Delrio, Gennaro Ciliberto, Michele Maio, Luigi Laghi, Fabio Grizzi, Tessa Fredriksen, Bénédicte Buttard, Lucie Lafontaine, Daniela Bruni, Anastasia Lanzi, Carine El Sissy, Nacilla Haicheur, Amos Kirilovsky, Anne Berger, Christine Lagorce, Christopher Paustian, Carmen Ballesteros-Merino, Jeroen Dijkstra, Carlijn van de Water, Shannon van Lent-van Vliet, Nikki Knijn, Ana-Maria Muşină, Dragos-Viorel Scripcariu, Boryana Popivanova, Mingli Xu, Tomonobu Fujita, Shoichi Hazama, Nobuaki Suzuki, Hiroaki Nagano, Kiyotaka Okuno, Toshihiko Torigoe, Noriyuki Sato, Tomohisa Furuhata, Ichiro Takemasa, Kyogo Itoh, Prabhu S Patel, Hemangini H Vora, Birva Shah, Jayendrakumar B Patel, Kruti N Rajvik, Shashank J Pandya, Shilin N Shukla, Yili Wang, Guanjun Zhang, Yutaka Kawakami, Francesco M Marincola, Paolo A Ascierto, Bernard A Fox, Franck Pagès, Jérôme Galon
PURPOSE: The purpose of this study was to evaluate the prognostic value of Immunoscore in patients with stage III colon cancer (CC) and to analyze its association with the effect of chemotherapy on time to recurrence (TTR). METHODS: An international study led by the Society for Immunotherapy of Cancer evaluated the predefined consensus Immunoscore in 763 patients with American Joint Committee on Cancer/Union for International Cancer Control TNM stage III CC from cohort 1 (Canada/United States) and cohort 2 (Europe/Asia)...
November 1, 2020: Journal of Clinical Oncology
https://read.qxmd.com/read/32669377/a-diagnostic-biopsy-adapted-immunoscore-predicts-response-to-neoadjuvant-treatment-and-selects-patients-with-rectal-cancer-eligible-for-a-watch-and-wait-strategy
#16
JOURNAL ARTICLE
Carine El Sissy, Amos Kirilovsky, Marc Van den Eynde, Ana-Maria Muşină, Maria-Gabriela Anitei, Alfredo Romero, Florence Marliot, Audelaure Junca, Jérôme Doyen, Bernhard Mlecnik, Nacilla Haicheur, Tessa Fredriksen, Christine Lagorce, Anne Jouret-Mourin, Daniel Leonard, Frédéric Bibeau, Soledad Iseas, Enrique L Roca, Ana M Cabanne, Carlos A Vaccaro, Juan P Santino, Eduardo Huertas, David Tougeron, Carlos Carvalho, Nuno Figueiredo, Rodrigo O Perez, Angelita Habr-Gama, Viorel Scripcariu, Jean-Pierre Gerard, Jérôme Galon, Guy Zeitoun, Franck Pagès
PURPOSE: No biomarker to personalize treatment in locally advanced rectal cancer (LARC) is currently available. We assessed in LARC whether a diagnostic biopsy-adapted immunoscore (ISB ) could predict response to neoadjuvant treatment (nT) and better define patients eligible to an organ preservation strategy ("Watch-and-Wait"). EXPERIMENTAL DESIGN: Biopsies from two independent cohorts ( n 1 = 131, n 2 = 118) of patients with LARC treated with nT followed by radical surgery were immunostained for CD3+ and CD8+ T cells and quantified by digital pathology to determine ISB ...
October 1, 2020: Clinical Cancer Research
https://read.qxmd.com/read/32455336/contribution-of-immunoscore-and-molecular-features-to-survival-prediction-in-stage-iii-colon-cancer
#17
JOURNAL ARTICLE
Frank A Sinicrope, Qian Shi, Fabienne Hermitte, Tyler J Zemla, Bernhard Mlecnik, Al B Benson, Sharlene Gill, Richard M Goldberg, Morton S Kahlenberg, Suresh G Nair, Anthony F Shields, Thomas C Smyrk, Jerome Galon, Steven R Alberts
BACKGROUND: The American Joint Committee on Cancer staging and other prognostic tools fail to account for stage-independent variability in outcome. We developed a prognostic classifier adding Immunoscore to clinicopathological and molecular features in patients with stage III colon cancer. METHODS: Patient (n = 559) data from the FOLFOX arm of adjuvant trial NCCTG N0147 were used to construct Cox models for predicting disease-free survival (DFS). Variables included age, sex, T stage, positive lymph nodes (+LNs), N stage, performance status, histologic grade, sidedness, KRAS/BRAF , mismatch repair, and Immunoscore (CD3+ , CD8+ T-cell densities)...
June 2020: JNCI Cancer Spectrum
https://read.qxmd.com/read/32085041/significant-differences-in-outcome-between-immunoscore-categories-in-stage-i-colon-cancer-patients
#18
JOURNAL ARTICLE
J Galon, F Hermitte, B Mlecnik, F Marliot, C Bifulco, A Lugli, I Nagtegaal, A Hartmann, M Van den Eynde, M Roehrl, P Ohashi, E Zavadova, T Torigoe, P Patel, Y Wang, Y Kawakami, F Marincola, P Ascierto, B Fox, F Pagès
No abstract text is available yet for this article.
July 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/30847467/automated-exploration-of-gene-ontology-term-and-pathway-networks-with-cluego-rest
#19
JOURNAL ARTICLE
Bernhard Mlecnik, Jérôme Galon, Gabriela Bindea
SUMMARY: Large scale technologies produce massive amounts of experimental data that need to be investigated. To improve their biological interpretation we have developed ClueGO, a Cytoscape App that selects representative Gene Onology terms and pathways for one or multiple lists of genes/proteins and visualizes them into functionally organized networks. Because of its reliability, userfriendliness and support of many species ClueGO gained a large community of users. To further allow scientists programmatic access to ClueGO with R, Python, JavaScript etc...
March 7, 2019: Bioinformatics
https://read.qxmd.com/read/30537506/the-link-between-the-multiverse-of-immune-microenvironments-in-metastases-and-the-survival-of-colorectal-cancer-patients
#20
JOURNAL ARTICLE
Marc Van den Eynde, Bernhard Mlecnik, Gabriela Bindea, Tessa Fredriksen, Sarah E Church, Lucie Lafontaine, Nacilla Haicheur, Florence Marliot, Mihaela Angelova, Angela Vasaturo, Daniela Bruni, Anne Jouret-Mourin, Pamela Baldin, Nicolas Huyghe, Karin Haustermans, Annelies Debucquoy, Eric Van Cutsem, Jean-Francois Gigot, Catherine Hubert, Alex Kartheuser, Christophe Remue, Daniel Léonard, Viia Valge-Archer, Franck Pagès, Jean-Pascal Machiels, Jérôme Galon
Treatment of metastatic colorectal cancer is based upon the assumption that metastases are homogeneous within a patient. We quantified immune cell types of 603 whole-slide metastases and primary colorectal tumors from 222 patients. Primary lesions, and synchronous and metachronous metastases, had a heterogeneous immune infiltrate and mutational diversity. Small metastases had frequently a low Immunoscore and T and B cell score, while a high Immunoscore was associated with a lower number of metastases. Anti-epidermal growth factor receptor treatment modified immune gene expression and significantly increased T cell densities in the metastasis core...
December 10, 2018: Cancer Cell
keyword
keyword
97185
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.